Introduction {#Sec1}
============

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 (Zhu *et al.* [@CR36]), has been rapidly spreading and causing a worldwide pandemic (Kirby [@CR11]; Saglietto *et al.* [@CR18]). The pneumonia induced by SARS-CoV-2 is known as coronavirus disease 2019 (COVID-19) (Ivers and Walton [@CR10]). To date, the virus has infected millions of people all over the world.

Recently, many studies about long-term viral duration in COVID-19 patients have been published (Liu *et al.* [@CR16]; Wan *et al.* [@CR24]; Zhou *et al.* [@CR35]; Shi *et al.* [@CR21]; Yang JR *et al.* [@CR28]; Li *et al.* [@CR14]). The longest duration observed was 83 days in one patient's upper respiratory tract samples (Li *et al.* [@CR14]). Although the association between viral duration and disease severity or older age was inconsistent in different studies, some studies reported longer viral duration correlated with severe disease or older age in COVID-19 patients (Yan *et al.* [@CR27]; Zhang YC *et al.* [@CR31]; Hu *et al.* [@CR8]). Besides, there are limited evidences about the infectivity of SARS-CoV-2 for patients with prolonged positivity of SARS-CoV-2 RNA (Walsh *et al.* [@CR23]). Thus, treating prolonged positive patients might be necessary during this COVID-19 pandemic.

By now, no anti-viral therapy has been proven effective in treating COVID-19. Convalescent plasma (CP) therapy is a classical passive antibody therapy used to treat viral pandemic historically, such as influenza A (HIN1) (Hung *et al.* [@CR9]), Ebola virus disease (Sahr *et al.* [@CR19]) and SARS (Cheng *et al.* [@CR4]). Recently case reports showed that CP collected from recovered patients might be effective to treat critically ill patients with COVID-19 (Zhang B *et al.* [@CR33]; Ahn *et al.* [@CR2]; Duan *et al.* [@CR7]; Shen *et al.* [@CR20]). However, in these studies, critically ill patients at the early stages of illness were mainly aimed. There is not any report about implementing CP therapy in patients with prolonged positivity of SARS-CoV-2 RNA.

We noticed that convalescent plasma was sometimes given to these patients with prolonged positivity of SARS-CoV-2 RNA. Herein, we perform a retrospective study to analyze the clinical benefit of CP therapy in patients with prolonged positivity of SARS-CoV-2 RNA.

Materials and Methods {#Sec2}
=====================

Design and Study Participants {#Sec3}
-----------------------------

This single-center retrospective observational study was performed in Jinyintan Hospital, which is one of the earliest designated hospitals for COVID-19 in Wuhan, China. Patients who confirmed COVID-19 admitted into Jinyintan Hospital from January 1 to April 20, 2020, were included for initial screen. We investigated all patients with COVID-19 who received CP therapy during hospitalization without enrolled in any other random control trial. Patients were excluded if their SARS-CoV-2 tests were negative before infusion of CP. The clinical outcomes (discharges, mortality, length of hospital stay) were monitored up to April 25, 2020. The discharged patients in Jinyintan Hospital must need to meet the following criteria: patients with two consecutive negative tests of respiratory specimens; patients' symptom resolved; no hospitalization was required as assessed by clinicians. In our study, all discharged patients still need to transport to other isolation sites for medical observation for 2 weeks.

In our study, we defined patients with tests of SARS-CoV-2 turned negative ≤ 7 days after the first infusion of CP to be in early negative group (EN group), others were defined to be in late negative group (LN group).

Clinical Information {#Sec4}
--------------------

Clinical information of patients was collected from the electronic medical information system of Jinyintan Hospital, including the following factors: demographic data; date of symptom onset, admission, first CP infusion and discharge; laboratory data before and after infusion of CP, including white blood cell count, neutrophil count, lymphocyte count, liver and kidney function test, and inflammatory factors such as high sensitive C-reaction protein (HsCRP); results of SARS-CoV-2 test and cycle threshold value (Ct value) of quantitative reverse transcription-polymerase chain reaction; patients' status and treatments before or after the CP therapy, including the vital signs, anti-virus therapy, oxygen therapy, and other treatments; total volume dose of CP; pulmonary imaging examination data; information on complications such as transfusion-related adverse reactions.

Quantitative Reverse Transcription-Polymerase Chain Reaction {#Sec5}
------------------------------------------------------------

Test of SARS-CoV-2 were performed in a laboratory in Jinyintan Hospital. Respiratory tract specimens (including nasopharyngeal, sputum, bronchial alveolar lavage fluid) collected from patient were transferred to the laboratory within 4 h. The quantitative reverse transcription-polymerase chain reaction (RT-PCR) of SARS-CoV-2 has already been described previously (Corman *et al.* [@CR6]). Total nucleic acid extraction was performed on the specimens using the RNA Viral Kit (Life River). The *E* gene, *N* gene, and *RdRP* gene of SARS-CoV-2 (located in ORFlab reading frame) was detected using a specific kit (Life River), which was approved by the China Food and Drug Administration. Ct value is the number of cycles required for the fluorescent signal to cross the threshold for a positive test, and a higher Ct value is correlated with lower viral load. According to the instruction of the kit, Ct values of specimens with *E* gene, *N* gene, and *RdRP* gene \< 43 were considered to be positive, and results were highly reliable.

Artificial Intelligence Analysis of Computed Tomography {#Sec6}
-------------------------------------------------------

The imaging artificial intelligence (AI)-assisted diagnostic system can quickly identify COVID-19, delineate and quantify lesions designed by the Chinese Academy of Sciences, National Biological Information Center, Tsinghua University, and Hospital of Zhongshan University. It is developed by applying advanced AI technologies, such as deep learning, transfer learning, and using the multiple neural network architecture training models. Besides AI, X-ray and computed tomography (CT) images of all patients have been manually reviewed by a group, consisting of three experienced imaging specialists.

CP of Donors {#Sec7}
------------

All CP were obtained from donors recovered from COVID-19, the interval between symptom onset and donation of donors were \> 3 weeks; all donors must meet the discharge standard of the seventh Trial Version of the New Coronavirus Pneumonia Prevention and Control Program (Chinese National Health Commission [@CR5]). All the donors were confirmed without transfusion-related infectious diseases before donation. Interval between discharge and donation must be \> 10 days. The neutralizing antibody titer was evaluated before transfusion, convalescent plasma with titer of \> 1:160 were used for patients in our study. After the clinician applying for a blood transfusion, convalescent plasma would be transferred from the blood center to the isolation ward on the same day.

Statistical Analysis {#Sec8}
--------------------

Data were expressed as categorical variable and continuous variable. To compare the EN group and LN group, Chi-square test was used to analyze the categorical variable. For the continuous variable, results of Data were shown as median and inter-quartile range (IQR). Mann--Whitney test was used to perform nonparametric test. A two-sided *P* value \< 0.05 were considered statistically significantly different between the two groups. SPSS 22.0 is used for statistical analysis.

Results {#Sec9}
=======

Demographics and Baseline Characteristics of Patients with Prolonged Positivity of SARS-CoV-2 RNA before CP Therapy {#Sec10}
-------------------------------------------------------------------------------------------------------------------

As shown in Table [1](#Tab1){ref-type="table"}, a total of 27 adult patients, with a median 44.0 (30.0--47.0) days between symptom onset and last positive test of SARS-CoV-2 RNA before CP therapy, were included. Their median age was 64.0 (57.0--72.0) years and 15 (55.5%) patients were male.Table 1Demographic and clinical characteristics of patient before CP therapy.CharacteristicTotal\
n = 27EN group\
n = 15LN group\
n = 12*P* valueAge, median (IQR)---y64.0 (57.0--72.0)63.0 (57.0--72.0)65.0 (56.2--78.0)0.581Male sex---no. (%)15 (55.5)6 (40)9 (75)0.121Coexisting chronic disease---no. (%) Hypertension12 (44.4)6 (40)6 (50)0.707 Coronary artery disease2 (7.4)1 (6.6)1 (8.3)1.000 Diabetes2 (7.4)1 (6.6)1 (8.3)1.000 Malignant tumor3 (11.1)2 (13.3)1 (8.3)1.000 Neurological disorders6 (22.2)3 (20)3 (25)1.000 Chronic kidney disease1 (3.7)01 (8.3) HIV/AIDS2 (7.4)02 (16.6) Chronic liver disease2 (7.4)01 (8.3)Laboratory tests before transfusion White-cell count, median (IQR)---(× 10^−9^/L)5.37 (4.81--7.99)6.49 (4.81--7.99)4.16(3.31--7.47)0.075 Neutrophil count, median (IQR)---(× 10^−9^/L)3.57 (2.58--5.58)4.25 (2.94--5.70)2.83(1.91--4.26)0.083 Lymphocyte count, median (IQR)---(× 10^−9^/L)1.24 (0.62--1.85)1.44 (0.46--1.85)1.07 (0.64--1.33)0.614 Platelet count, median (IQR)---(× 10^−9^/L)175 (137--194)185 (163--219)148 (78--183)0.054 Hematocrit, median (IQR)---(%)33.4 (28.4--38.4)33.4 (26.4--40.1)34.1 (28.7--38.3)0.943 Serum creatinine, median (IQR)---(μmol/L)69.1 (57.4--75.0)66.0 (56.0--75.0)70.5 (59.0--112.0)0.683Total bilirubin, median (IQR)---(μmol/L)11.4 (8.6--18.0)11.9 (9.4--18.0)10.8(8.1--20.0)0.648 Alanine aminotransferase, median (IQR)--- (U/L)17.0 (10.0-28.0)24.0 (13.0--33.0)13.0 (8.5--26.0)0.103 Aspartate aminotransferase, median (IQR)---(U/L)26.0 (20.0--42.0.0)27.0 (21.0--60.0)24.5 (15.5--34.5)0.516 High-sensitivity C-reactive protein, median (IQR)---(mg/L)3.1 (0.8--37.8)3.1 (0.8--38.1)3.9 (0.7--42.8)0.733

We conducted a subgroup analysis between patients of EN group and LN group. Demographic data was shown as Table [1](#Tab1){ref-type="table"}, median age, percentage of male patients, coexisting chronic diseases of patients in both groups were not significantly different (Table [1](#Tab1){ref-type="table"}). Each patient of both groups underwent laboratory tests before CP therapy including white cell count, neutrophil count, lymphocyte count, platelet count, hematocrit, serum creatinine test, serum total bilirubin, serum alanine aminotransferase, serum aspartate aminotransferase, and hsCRP test, and the results were shown as Table [1](#Tab1){ref-type="table"}.

As shown in Table [2](#Tab2){ref-type="table"}, patients in both groups have a longer median interval between symptom onset and date of CP transfusion as compared to former reports \[40.0 (26.0--47.0) days in EN group and 45.5 (41.2--57.0) days in LN group\]. The median body temperature and oxygen therapy before CP transfusion were not significant different. The median fraction of inspiration O~2~ (FiO~2~), peripheral oxygen saturation and anti-viral therapies of both groups before CP therapy are shown in Table [2](#Tab2){ref-type="table"}. Before transfusion, eight patients in EN group and seven in LN group received broad-spectrum antibiotic therapy, three patients in EN group and two in LN group received corticoid therapy after admission. Four patients in EN group and two in LN group received infusion of immunoglobulin after admission. As shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, demographics and baseline characteristics of patients in EN group and LN group were not significant different before CP therapy.Table 2Patients' status and treatments received before CP therapy.CharacteristicTotal\
n = 27EN group\
n = 15LN group\
n = 12*P* valueInterval between symptom onset and transfusion, median (IQR)---d45.0 (35.0--49.0)40.0 (26.0--47.0)45.5 (41.2--57.0)0.075Interval between symptom onset and last positive test before CP therapy, median (IQR)---d44.0 (30.0--47.0)39.0 (24.0--45.0)44.5 (38.2--54.7)0.126Body temperature, median (IQR)---°C36.9 (36.6--37.0)36.8 (36.5--37.2)36.9 (36.7--37.0)0.516Fever---no. (%)6 (22.2)4 (26.6)2 (16.6)0.662Oxygen therapy---no. (%) No oxygen treatment19 (70.3)10 (66.6)9 (75.0)0.696 Nasal catheter oxygen therapy3 (11.1)3 (20)0 (0) Mechanical ventilation5 (18.5)2 (13.3)3 (25.0)1.000 Extracorporeal membrane oxygenation1 (3.7)1 (6.6)0 (0) Fraction of inspiration O~2~ (n = 26), median (IQR)---%21.0 (21.0--33.0)21.0 (21.0--33.0)21.0 (21.0--35.2)0.809 Respiratory rate \> 24 times/min---no. (%)5 (18.5)3 (20)2 (16.6)1.000 Peripheral oxygen saturation, median (IQR)---%98.0 (97.0--99.0)97.0 (97.0--99.0)97.0 (97.0--98.5)0.905 Vasopressors---no. (%)4 (14.8)1 (6.6)3 (25.0)0.294Anti-virus therapy---no. (%) Ribavirin4 (14.8)2 (13.3)2 (16.6)1.000 Lopinavir8 (29.6)3 (20.0)5 (41.6)0.398 Favipiravir2 (7.4)2 (13.3)0 (0) Definite or suspected coinfection---no. (%)6 (22.2)3 (20.0)3 (25.0)0.433 Broad-spectrum antibiotic therapy---no. (%)15 (55.5)8 (53.3)7 (58.3)1.000 Corticoid therapy---no. (%)5 (18.5)3 (20)2 (16.6)1.000 Immunoglobulin therapy---no. (%)6 (22.2)4 (26.6)2 (16.6)0.662

Clinical Benefit and Outcome of Patients with Prolonged Positivity of SARS-CoV-2 RNA after CP Therapy {#Sec11}
-----------------------------------------------------------------------------------------------------

As shown in Table [3](#Tab3){ref-type="table"}, the median and interquartile ranged total volume of CP transfusion was 400 (200--400) mL in EN group and 400 (400--800) mL in LN group. No adverse reactions related to blood transfusion were found during infusion in both groups. The median interval between transfusion and discharge was 7.0 (4.0--11.0) days in EN group and 24.0 (14.7--28.7) days in LN group. Most patients underwent X-ray or CT scan before and after transfusion (EN group = 8; LN group = 12), and pulmonary imaging improvement was confirmed in 7 patients in EN group and 8 in LN group after CP therapy.Table 3Patients' status after transfusion and outcome after CP therapy.CharacteristicTotal\
n = 27EN group\
n = 15LN group\
n = 12*P* valueTotal volume dose of CP, median (IQR)---mL400 (200--600)400 (200--400)400 (400--800)0.861Transfusion-related adverse reactions---no. (%)0 (0)0 (0)0 (0)Interval between first transfusion and discharge, median (IQR)---d11.0 (6.0--25.0)7.0 (4.0--11.0)24.0 (14.7--28.7)Pulmonary imaging improvement15/207/88/120.603Length of hospital stay, median (IQR)---d43.0 (24.0--54.0)37.0 (19.0--50.0)52.0 (35.0--63.7)Mortality of 60 days---no. (%)3 (11.1)0 (0)3 (25)

The median length of hospitalization in EN group was 37.0 days and 52.0 days in LN group, as shown in Table [3](#Tab3){ref-type="table"}. Due to the definition of EN group and LN group, the median length of hospitalization in LN group was much longer than EN group, thus we didn't make a comparative analysis. Three patients died in LN group within 60 days, two died from refractory hypoxemia and one in LN group died from severe septic shock. No patients died in EN group within 60 days.

Comparison of Lung Imaging before and after CP Therapy in Patients with Prolonged Positivity of SARS-CoV-2 RNA {#Sec12}
--------------------------------------------------------------------------------------------------------------

Five patients in our study underwent CT scan before (within 3 days) and reexamination after transfusion (within 5--8 days). For these patients, comparison and analysis of CT images were performed before and after transfusion by using the AI-assisted diagnostic system described above (Fig. [1](#Fig1){ref-type="fig"}A, [1](#Fig1){ref-type="fig"}B). Three (60%) patients showed as consolidation of CT images before CP therapy (Fig. [1](#Fig1){ref-type="fig"}C), five all showed as ground-glass opacity (GGO) (Fig. [1](#Fig1){ref-type="fig"}D) before CP therapy, which were similar to the former report about CT findings in COVID-19 patients (Adair and Ledermann [@CR1]). After transfusion, the total consolidation percentage decreased after transfusion in three patients (Fig. [1](#Fig1){ref-type="fig"}C), and the total GGO percentage decreased in five all patients' CT images (Fig. [1](#Fig1){ref-type="fig"}D).Fig. 1CT images before and after CP therapy. **A** Results of AI-assisted diagnostic system in patient 2 before CPT, blue areas represent GGO in CT images, red areas represent consolidation in CT images. **B** Results of AI-assisted diagnostic system in patient 2 after CPT. **C** Consolidation of CT in patients 1, 2, and 3 decreased after the transfusion. **D** GGO of CT in patients 1, 2, 3, 4, and 5 decreased after CP therapy.

Variation Trend of Viral Load before and after CP Therapy in Patients with Prolonged Positivity of SARS-CoV-2 RNA {#Sec13}
-----------------------------------------------------------------------------------------------------------------

After admission, patients in both groups underwent SARS-CoV-2 tests by using RT-PCR as described above. The variation trend of Ct value in both groups are show as Fig. [2](#Fig2){ref-type="fig"}. The median Ct value on admission is 33.0 (28.7--38.2) in EN group and 32.5 (22.1--38.1) in LN group, without significant differences (*P *= 0.591, Fig. [2](#Fig2){ref-type="fig"}). Besides, the median Ct values was not significant between EN group and LN group before transfusion \[34.0 (26.4--38.3) *vs*. 30.9 (26.7--35.7), *P *= 0.591, Fig. [2](#Fig2){ref-type="fig"}\]. After transfusion, Ct values of patients in EN group increased and \> 43 within 7 days gradually and most of them (n = 13) discharged within 10 days and were unable to detect at 9, 12, and 15 days. Conversely, the median Ct values of patients in LN group remained \< 43 at 3, 5, 7, 9, and 12 days after transfusion, 6 patients in LN group still remained \< 43 at 15 days after transfusion (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Variation trend of viral load of patients before and after CP therapy: Ct value of \< 43 is defined to be positive, and Ct value of \> 47 would be undetectable. \*The median Ct value in early negative group (ENG) was significantly greater than late negative group (LNG) on day 3 after the transfusion, *P* = 0.043. \*\*: The median Ct value in early negative group was significantly greater than late negative group on day 5, *P* = 0.008. \*\*\*: The median Ct value in early negative group was significantly greater than late negative group on day 7, *P *= 0.003.

Discussion {#Sec14}
==========

Our study explored the efficiency of CP therapy in COVID-19 patients at a later stage of the illness. All patients with prolonged positivity of SARS-CoV-2 RNA in our study were implemented CP therapy including mild cases. We confirmed that the viral load rapidly decreased after CP therapy in some patients (EN group), whereas others remain positive 7 days after CP therapy (LN group). The difference in baseline information, viral load, and other interventions was not significant before transfusion. After CP therapy, more than half patients obtained a rapid decrease of viral load.

CP therapy is a classic therapy against pandemic that can be traced back to the early twentieth century and clinicians treated the 1918 Spanish influenza with convalescent sera (Luke *et al.* [@CR17]), which was found to be effective in decreasing the mortality of 1918 Spanish influenza pandemic. In the 21st century researches have shown that CP therapy effectively and safely treats H1N1 and SARS at the early stage of illness. Besides SARS and H1N1, there is also some anecdotal information on the use of convalescent serum in seriously ill individuals. Two patients diagnosed with Ebola viral disease received CP therapy on the early stage of illness (day 8 and 3 after symptom onset) and recovered without serious long-term sequelae to date (Kraft *et al.* [@CR13]). One patient diagnosed with H5N1 received CP therapy on day 8 after symptom onset recovered and successfully discharged (Zhou *et al.* [@CR34]). Thus, CP therapy might be an effective therapy for certain viral diseases, especially in early stage of illness.

However, to our knowledge, no reports about convalescent plasma therapy in viral disease at later stage have been published. Recently one case report suggests efficiency of CP therapy in treating 5 patients with severe COVID-19 (Corman *et al.* [@CR6]), the interval between the symptom onset and transfusion was \< 20 days. However, the interval in our study is much longer than the previously mentioned report. In our study, empirical anti-viral therapies were already implemented in these patients, but Ct value of respiratory tract specimens collected from these patients were still \< 43 before CP therapy, represented a high viral load. These patients with prolonged positivity of SARS-CoV-2 RNA \[44.0 (30.0--47.0) days\] still needed to hospitalize and separate, which may cause a huge cost during COVID-19 pandemic. In fact, individual human case studies reported long periods of viral shedding that in Middle East respiratory syndrome (MERS) pandemic (Kraaij-Dirkzwager *et al.* [@CR12]; Spanakis *et al.* [@CR22]). One report showed that 42-days positive test outcome in RT-PCR assay of MERS in a healthcare worker in Saudi Araba (Al-Gethamy *et al.* [@CR3]). Recently, a report have shown long-term coexisting of SARS-CoV-2 in some patients, and one of them did not produce any SARS-CoV-2---specific IgG with a positive test of SARS-CoV-2 in sputum after 46 days of illness (Wang B *et al.* [@CR25]). No specific therapies have proven to treat patients with prolonged positivity of SARS-CoV-2 RNA. In our study, more than half of the prolonged positive patients (EN group) met the discharge standard within 7 days and discharged rapidly after CP therapy. Thus, patients with prolonged positivity of SARS-CoV-2 RNA might benefit from CP therapy with shorter length of hospitalization and less cost. Besides, RT-PCR of SARS-CoV-2 turned negative within 15 days after first infusion in five patients in LN group, one turned negative at 21 days, and six were still positive until the deadline.

Our research showed that the viral load of the respiratory tract specimen in two groups differed after CP therapy. Viral load may correlate with transmission potential in COVID-19 (Little *et al.* [@CR15]). Recently, a report have shown viral load that was detected in the asymptomatic patient was similar to that in the symptomatic patients, which suggested the transmission potential of asymptomatic or minimally symptomatic patients (Zou *et al.* [@CR37]). Besides, CP treatment may discontinue SARS-CoV-2 shedding although didn't reduce mortality in critically end-stage COVID-19 patients (Zeng *et al.* [@CR32]). In our study most patients might still remain transmission potential even though symptom were mild before CP therapy. Thus, implementing CP therapy in patients with prolonged positivity of SARS-CoV-2 RNA might help to decrease viral road and potential of transmission in our study.

In addition, Reports suggests the mortality of severe COVID-19 patients was more than 60% at 28 days (Yang X *et al.* [@CR30], [@CR29]; Wang Z *et al.* [@CR26]). Whether CP therapy can reduce mortality of patient with COVID-19 is unclear in our study. Symptoms of most patients in our study were mild, so we didn't do a mortality analysis. After CP therapy, three patients in LN group died in our study. We assumed that virus duration might be a vital reason of death in these three patients for their viral durations were quite long (59, 53, 53 days).

This study has several limitations. First, it is a retrospective observational study, a randomized double-blind trial would be more accurate to assess the efficacy of CP therapy in COVID-19. Second, symptoms of most patients in our study were mild, including more critically ill patients would be helpful in determining whether CP therapy could reduce mortality in COVID-19. Third, no studies have reported the appropriate time and dosage of CP implemented in patients with COVID-19; therefore, all decisions of CP therapy intervention were made by clinicians empirically. Forth, we did not monitor the neutralizing antibody in patients after CP therapy.

In conclusion, this retrospective observational study on CP therapy shows that patients with prolonged positivity of SARS-CoV-2 RNA can benefit from a rapid decrease of viral load and improvement in pulmonary images. The appropriate time to implement CP therapy and the optimal CP dosage are still to be explored in the future.
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